New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

European Union lawmakers designed EU Clinical Trial Regulation 536/2014 to heighten interest within the healthcare industry for planning and conducting clinical trials in the EU, which experienced ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The EU has published new recommendations aiming to encourage the use of decentralised clinical trials (DCTs) – and to make sure patients who participate in them have their wellbeing safeguarded ...

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

"I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team,” stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance.